What is driving GV.PA stock today?

Today’s move is driven by high trading volume of 38,489,238 shares and speculative interest. There was no major company release; volume pushed the price from €0.0018 to €0.0020.

What is Meyka AI’s outlook for GV.PA stock?

Meyka AI’s forecast model projects a 12-month target of €0.00400, implying upside of 122.22% versus the current €0.0018. Forecasts are projections and not guarantees.

What are the main risks for GV.PA investment?

Key risks include weak profitability (EPS -0.11), limited cash per share, potential dilution from fundraising, and high volatility from low price and float.

Where can I find official company information for GV.PA?

Official company details and filings are available on Genomic Vision’s website at https://www.genomicvision.com. For live market data use your trading platform or Meyka’s GV.PA stock page.

EU Stocks

GV.PA Genomic Vision (EURONEXT) +5.88% intraday 16 Mar 2026: liquidity and forecast focus

ByDanny Kontos March 16, 2026March 16, 2026

GV.PA stock is trading up intraday after heavy volume as investors watch liquidity and fundamentals. Genomic Vision SA (GV.PA) on EURONEXT changed to €0.0018, a +5.88% move with 38,489,238 shares traded and a day range of €0.0015–€0.0020. We highlight the drivers behind the spike, the balance-sheet pressures shown by EPS -0.11, and short-term trading signals. Meyka AI provides real-time context and model-based forecasts to help place today’s activity in the wider Europe healthcare sector.